Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Total Liabilities (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Total Liabilities data on record, last reported at $57.4 million in Q4 2025.

  • For Q4 2025, Total Liabilities fell 11.42% year-over-year to $57.4 million; the TTM value through Dec 2025 reached $57.4 million, down 11.42%, while the annual FY2025 figure was $57.4 million, 11.42% down from the prior year.
  • Total Liabilities reached $57.4 million in Q4 2025 per ACRS's latest filing, up from $55.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $64.8 million in Q4 2024 and bottomed at $27.2 million in Q2 2024.
  • Average Total Liabilities over 5 years is $50.5 million, with a median of $53.4 million recorded in 2021.
  • Peak YoY movement for Total Liabilities: crashed 51.25% in 2024, then surged 110.68% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $53.9 million in 2021, then grew by 5.76% to $57.0 million in 2022, then decreased by 29.4% to $40.2 million in 2023, then skyrocketed by 61.02% to $64.8 million in 2024, then dropped by 11.42% to $57.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $57.4 million in Q4 2025, $55.4 million in Q3 2025, and $57.4 million in Q2 2025.